澳大利亚体外膜氧合后6个月死亡或残疾发生率:一项前瞻性、多中心、注册登记嵌入式队列研究
该研究为澳大利亚23家医院前瞻性、多中心、注册登记嵌入式队列研究,纳入2019年2月15日至2020年12月31日ICU内接受ECMO的成人患者。主要终点为ECMO启动后6个月死亡或中重度残疾(WHODAS 2.0 12项调查定义)。391例有结局数据患者中260例(66%)发生主要终点:VA-ECMO 136/202(67%)、VV-ECMO 60/111(54%)、eCPR 64/78(82%)。校正后eCPR者死亡或中重度残疾高于VV-ECMO(RD -32%,95%CI -49至-15;p<0.001),与VA-ECMO无显著差异(RD -8%,95%CI -22至6;p=0.27)。作者认为需对ECMO存活者提供长期多学科照护与支持。
要点
- ECMO启动后6个月死亡或中重度残疾总体为260/391(66%),仅约三分之一患者存活且无中重度残疾。
- eCPR者6个月死亡或中重度残疾为64/78(82%),高于VV-ECMO的60/111(54%)和VA-ECMO的136/202(67%)。
- 校正年龄、合并症、APACHE IV评分、ICU入住至ECMO启动天数及ECMO前血管升压药使用后,eCPR者死亡或中重度残疾高于VV-ECMO(RD -32%,95%CI -49至-15;p<0.001)。
- 校正后eCPR与VA-ECMO的死亡或中重度残疾无显著差异(RD -8%,95%CI -22至6;p=0.27)。
- 作者指出残疾在所有功能领域均常见,提示ECMO存活者需要长期、多学科照护与支持。
适用人群与场景
- 澳大利亚23家参与中心ICU内接受ECMO的成人(≥18岁)患者,ECMO支持指征为呼吸衰竭、心衰或心脏骤停,研究期间为2019年2月15日至2020年12月31日。
- EXCEL注册登记纳入研究期间在参与中心ICU接受ECMO的全部澳大利亚成人;本研究报告442例入组患者中391例(88%)有结局数据。
研究设计与关键结果
- 研究类型:前瞻性、多中心、注册登记嵌入式队列研究,澳大利亚23家医院,2019年2月15日至2020年12月31日,442例入组,391例(88%)有结局数据。
- 主要终点为ECMO启动后6个月死亡或中重度残疾(WHODAS 2.0 12项调查定义),391例中260例(66%)发生。
- 按ECMO模式:VA-ECMO 136/202(67%)、VV-ECMO 60/111(54%)、eCPR 64/78(82%)发生死亡或中重度残疾。
- 校正年龄、合并症、APACHE IV评分、ICU入住至ECMO启动天数及ECMO前血管升压药使用后,eCPR者死亡或中重度残疾高于VV-ECMO(VV-ECMO vs eCPR:RD -32%,95%CI -49至-15;p<0.001)。
- 校正后eCPR与VA-ECMO的死亡或中重度残疾无显著差异(VA-ECMO vs eCPR:RD -8%,95%CI -22至6;p=0.27)。
证据类型、等级与局限
- 证据类型:前瞻性、多中心、注册登记嵌入式队列研究(EXCEL注册登记,ClinicalTrials.gov NCT03793257)。
- 局限:作者指出需进一步研究以了解不同诊断、接受不同ECMO模式患者的180天及更长期预后。
对床旁实践的改变
- 作者认为残疾在所有功能领域均常见,提示需要对接受过ECMO的存活患者提供长期、多学科照护与支持。
- 作者指出需进一步研究不同诊断和不同ECMO模式患者的180天及更长期预后,这可能对ECMO患者选择及ICU管理策略有重要影响。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Extracorporeal membrane oxygenation (ECMO) is an invasive procedure used to support critically ill patients with the most severe forms of cardiac or respiratory failure in the short term, but long-term effects on incidence of death and disability are unknown. We aimed to assess incidence of death or disability associated with ECMO up to 6 months (180 days) after treatment.
METHODS: This prospective, multicentre, registry-embedded cohort study was done at 23 hospitals in Australia from Feb 15, 2019, to Dec 31, 2020. The EXCEL registry included all adults (≥18 years) in Australia who were admitted to an intensive care unit (ICU) in a participating centre at the time of the study and who underwent ECMO. All patients who received ECMO support for respiratory failure, cardiac failure, or cardiac arrest during their ICU stay were eligible for this study. The primary outcome was death or moderate-to-severe disability (defined using the WHO Disability Assessment Schedule 2.0, 12-item survey) at 6 months after ECMO initiation. We used Fisher's exact test to compare categorical variables. This study is registered with ClinicalTrials.gov, NCT03793257.
FINDINGS: Outcome data were available for 391 (88%) of 442 enrolled patients. The primary outcome of death or moderate-to-severe disability at 6 months was reported in 260 (66%) of 391 patients: 136 (67%) of 202 who received veno-arterial (VA)-ECMO, 60 (54%) of 111 who received veno-venous (VV)-ECMO, and 64 (82%) of 78 who received extracorporeal cardiopulmonary resuscitation (eCPR). After adjustment for age, comorbidities, Acute Physiology and Chronic Health Evaluation (APACHE) IV score, days between ICU admission and ECMO start, and use of vasopressors before ECMO, death or moderate-to-severe disability was higher in patients who received eCPR than in those who received VV-ECMO (VV-ECMO vs eCPR: risk difference [RD] -32% [95% CI -49 to -15]; p<0·001) but not VA-ECMO (VA-ECMO vs eCPR -8% [-22 to 6]; p=0·27).
INTERPRETATION: In our study, only a third of patients were alive without moderate-to-severe disability at 6 months after initiation of ECMO. The finding that disability was common across all areas of functioning points to the need for long-term, multidisciplinary care and support for surviving patients who have had ECMO. Further studies are needed to understand the 180-day and longer-term prognosis of patients with different diagnoses receiving different modes of ECMO, which could have important implications for the selection of patients for ECMO and management strategies in the ICU.
FUNDING: The National Health and Medical Research Council of Australia.
参考来源
- Hodgson CL, Higgins AM, Bailey MJ, et al. Incidence of death or disability at 6 months after extracorporeal membrane oxygenation in Australia: a prospective, multicentre, registry-embedded cohort study. Lancet Respir Med. 2022. PMID: 36174613. doi:10.1016/S2213-2600(22)00248-X
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。